Micromet secures $120 million despite sagging economy

September 22, 2009

Biopharmaceutical company Micromet closed $80.5 million in funding last month after a public offering of 14 million shares of common stock. Earlier in the year, the company raised $40 million.

The company’s main product is the BiTE antibody blinatumomab (MT103), which is currently in a phase II trial for the treatment of acute lymphoblastic leukemia (ALL).

Preliminary results from the phase II German Multicenter ALL Study Group (GMALL) were presented at the 2009 Congress of the European Hematology Association in Berlin. Eighty-one percent of the evaluated patients showed a minimal residual disease response, according to Micromet.

TOPIC INDEX

Cancer Types
Breast Breast (HER2+) Breast (Triple-Negative) CML Colorectal Gastrointestinal GIST Genitourinary Gynecologic Head & Neck	Hematology Kidney (Renal Cell) Leukemia Lung Lymphoma Melanoma Multiple Myeloma Ovarian Prostate Sarcoma
Supportive Care	More Topics
Bone Metastases End-of-Life Care Palliative Care	Ethics in Oncology Practice Management Practice & Policy

All Topics

FROM PHYSICIANS PRACTICE

Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND, May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.

VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri, May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?

Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC, May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.

Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson, May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.

Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker, May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.

Micromet secures $120 million despite sagging economy

Join the Conversation